**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2024

Commission File Number: 001-41641

**SHL TELEMEDICINE LTD.**

 (Translation of registrant’s name into English)

**90 Yigal Alon Street**

**Tel Aviv 67891, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒             Form 40-F ☐

**EXPLANATORY NOTE**

On March 14, 2024, SHL Telemedicine Ltd. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1. This Form 6-K is incorporated by reference into the Company's Registration Statement on [Form S-8 filed with the Securities and Exchange Commission on June 9, 2023 (Registration No. 333-272546)](https://www.sec.gov/Archives/edgar/data/1166834/000110465923069887/tm2318344d1_s8.htm).

|  |  |
| --- | --- |
| Exhibit | Description |

|  |  |
| --- | --- |
| [99.1](file:///\\FS\edgar\EDGAR%20Filing\SHL%20TELEMEDICINE%20LTD\2431135\exhibit_99-1.htm) | [Press release, dated March 14, 2024, issued by the Company.](file:///\\FS\edgar\EDGAR%20Filing\SHL%20TELEMEDICINE%20LTD\2431135\exhibit_99-1.htm) |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |
| --- | --- |
|  | **SHL Telemedicine Ltd.**  By: /s/ Amir Hai        Amir Hai        Chief Financial Officer |

March 14, 2024

**Exhibit 99.1**

Press release

Ad hoc announcement pursuant to Art. 53 LR

**SHL announces change in CEO position**

**Tel Aviv / Zurich / New York, March 14, 2024** - SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today that after over twenty years with SHL, Erez Nachtomy, CEO of SHL in the past four years will be stepping down as CEO in mid-June 2024.

Yariv Alroy, Chairman of SHL Telemedicine noted: “On behalf of the Board of Directors we would like to thank Erez for successfully leading SHL through a challenging period, and we sincerely thank him for his service and leadership.”

Erez Nachtomy, commented: “After nearly four years as CEO during a very intensive period, I feel this is a good point to hand over leadership. I would like to thank the Board of Director for their support during my tenure. Furthermore, I want to express my appreciation to all the amazing people across the Company for their hard work over the years. I will work closely with the Company and the Board to ensure a smooth transition and continued success for SHL.”

The Board of Directors of the Company will shortly commence a search for a new CEO, both internally and externally.

**About SHL Telemedicine**  
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).

For more information, please visit our website at www.shl-telemedicine.com.

**Contacts**

Fabienne Farner, IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch

**Forward-Looking Statements**  
*Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements*.